219332
β-连环蛋白/Tcf抑制剂III,iCRT3
The β-Catenin/Tcf Inhibitor III, iCRT3 controls the biological activity of β-Catenin/Tcf. This small molecule/inhibitor is primarily used for Biochemicals applications.
同義詞:
β-连环蛋白/Tcf抑制剂III,iCRT3, C3, 2-(((2-(4-乙基苯基)-5-甲基-1,3-恶唑-4-基)甲基)磺酰基)-N-(2-苯基乙基)乙酰胺,β-连环蛋白响应转录的抑制剂,Wnt通路抑制剂VIII
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式(希爾表示法):
C23H26N2O2S
分子量::
394.53
分類程式碼代碼:
12352200
NACRES:
NA.77
推薦產品
品質等級
化驗
≥95% (HPLC)
形狀
powder
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
tan
溶解度
DMSO: 50 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
一般說明
一种可渗透细胞的恶唑化合物,可通过直接的β-连环蛋白(β-cat)结合干扰β-cat-TCF4相互作用,从而作为选择性CRT(β-连环蛋白响应转录)抑制剂(IC50=8.2 nM,针对HEK293培养物中Wnt3a依赖性SuperTopFlash STF16-luc报告基因活性),同时表现出对音猬因子,JAK/STAT或Notch信号通路依赖性转录激活的活性大大降低。以剂量依赖性方式(25至75 µM)有效抑制CRT靶基因(包括WISP1,AXN2和CYCD1)的细胞表达,并选择性抑制HCT116(75 µM),HT29(75 µM)和几种需要持续Wnt/CRT活性才能存活的原代人结肠癌培养物(6.25至100 µg/mL;平均IC50 ~36 µg/ml)的增殖。
包裝
用惰性气体包装
警告
毒性:标准处理(A)
重構
复溶后,等分并冷冻保存(-20°C)。储备液在-20°C条件下可稳定保存3个月。
其他說明
Lee, E., et al. 2013.Proc.Natl.Acad.Sci. USA110, 15710.
Gonsalves, F.C., et al. 2011.Proc.Natl.Acad.Sci. USA108, 5954.
Gonsalves, F.C., et al. 2011.Proc.Natl.Acad.Sci. USA108, 5954.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。
Eugine Lee et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(39), 15710-15715 (2013-09-11)
Androgen receptor (AR) is the major therapeutic target in aggressive prostate cancer. However, targeting AR alone can result in drug resistance and disease recurrence. Therefore, simultaneous targeting of multiple pathways could in principle be an effective approach to treating prostate
Foster C Gonsalves et al.
Proceedings of the National Academy of Sciences of the United States of America, 108(15), 5954-5963 (2011-03-12)
Misregulated β-catenin responsive transcription (CRT) has been implicated in the genesis of various malignancies, including colorectal carcinomas, and it is a key therapeutic target in combating various cancers. Despite significant effort, successful clinical implementation of CRT inhibitory therapeutics remains a
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務